



UNIVERSITY OF LEEDS

This is a repository copy of *Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/97010/>

Version: Supplemental Material

Article:

van de Hulle, T, den Exter, PL, Planquette, B et al. (22 more authors) (2016) Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. *Journal of Thrombosis and Haemostasis*, 14 (1). pp. 105-113. ISSN 1538-7933

<https://doi.org/10.1111/jth.13172>

© 2015, International Society on Thrombosis and Haemostasis. This is the peer reviewed version of the following article: van de Hulle, T, den Exter, PL, Planquette, B et al. (22 more authors) (2016) Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. *Journal of Thrombosis and Haemostasis*, 14 (1). pp. 105-113. ISSN 1538-7933, which has been published in final form at <https://doi.org/10.1111/jth.13172>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplement 3: Additional results

Table i: Baseline characteristics of the individual cohorts

Characteristic	First author of cohort										
	Sahut D'Izarn	Shteinberg	Tiseo	Abdel-Razeq	den Exter	Soler	Jimenez	Donnelly	Bozas	Shinagare	O'Connell
Country	France	Israel	Italy	Jordan	The Netherlands	Spain	Spain	United Kingdom	United Kingdom	United States	United States
Design	Retrospective	Retrospective	Retrospective	Retrospective	Retrospective	Prospective	Retrospective	Retrospective	Prospective	Retrospective	Retrospective
Inclusion period	2006-2010	2002-2007	2006-2009	2004-2010	2001-2012	2007-2013	2003-2012	2008-2013	2010-2011	2004-2009	2003-2006
Patients, n	63	35	21	33	68	204	36	129	81	202	70
Incomplete follow-up	0	7	0	0	0	0	0	1	0	7	1
Mean age (SD; range)	67 (11; 42-86)	72 (13; 42-94)	64 (11;40-78)	59 (12; 27-82)	64 (15; 19-84)	69 (11; 31-92)	70 (11; 46-87)	65 (12; 28-90)	65 (11; 27-88)	60 (11; 21-90)	64 (12; 27-91)
Male sex, n (%)	31 (49)	9 (32)	12 (57)	13 (39)	40 (59)	121 (59)	14 (39)	72 (56)	54 (67)	81 (42)	44 (64)
Heart failure, n (%)	2 (3.2)	4 (14)	5 (24)	4 (12)	3 (4.4)	7 (3.4)	0 (0)	-	2 (2.5)	-	-
COPD, n (%)	1 (1.6)	2 (7.1)	0 (0)	2 (6.1)	5 (7.4)	16 (7.8)	4 (11)	-	5 (6.2)	-	-
Previous VTE, n (%)	8 (13)	4 (14)	2 (9.5)	-	3 (4.4)	12 (5.9)	2 (5.6)	-	4 (4.9)	-	12 (17)
Metastatic cancer, n (%)	44 (70)	-	19 (90)	19 (58)	53 (78)	119 (58)	19 (53)	104 (81)	62 (77)	-	62 (90)
Type of malignancy											
Lung, n (%)	18 (29)	6 (21)	21 (100)	5 (15)	13 (19)	33 (16)	6 (17)	20 (16)	10 (12)	38 (19)	6 (8.7)
Colorectal, n (%)	9 (14)	5 (18)	0 (0)	4 (12)	7 (10)	59 (29)	13 (36)	19 (15)	20 (25)	23 (12)	26 (38)
Other gastrointestinal, n (%)	10 (16)	3 (11)	0 (0)	9 (27)	12 (18)	32 (16)	7 (19)	36 (28)	23 (28)	42 (22)	13 (19)
Breast, n (%)	6 (9.5)	1 (3.6)	0 (0)	3 (9.1)	7 (10)	11 (5.4)	4 (11)	13 (10)	3 (3.7)	16 (8.2)	1 (1.4)
Gynaecological, n (%)	11 (17)	3 (11)	0 (0)	4 (12)	6 (8.8)	7 (3.4)	2 (5.6)	7 (5.5)	0 (0)	22 (11)	2 (2.9)
Other, n (%)	9 (14)	7 (25)	0 (0)	3 (9.1)	16 (24)	55 (27)	4 (11)	28 (22)	21 (26)	43 (22)	20 (29)
Haematological, n (%)	0 (0)	3 (11)	0 (0)	5 (15)	7 (10)	7 (3.4)	0 (0)	5 (3.9)	4 (4.9)	11 (5.6)	1 (1.4)
Largest pulmonary artery involved											
Central, n (%)	17 (27)	12 (43)	2 (9.5)	20 (61)	20 (29)	22 (11)	2 (5.6)	-	44 (54)	120 (62)	33 (48)
Peripheral, n (%)	46 (73)	12 (43)	19 (90)	13 (39)	46 (68)	178 (87)	33 (92)	-	37 (46)	75 (38)	36 (52)
Unspecified, n (%)	0 (0)	4 (14)	0 (0)	0 (0)	2 (2.9)	4 (2.0)	1 (2.8)	-	0 (0)	0 (0)	0 (0)
Treatment											
LMWH, n (%)	55 (87)	17 (61)	10 (48)	28 (85)	40 (59)	180 (88)	30 (83)	100 (78)	74 (91)	166 (85)	32 (46)
VKA, n (%)	2 (3.2)	0 (0)	0 (0)	1 (3.0)	28 (41)	24 (12)	3 (8.3)	6 (4.7)	7 (8.6)	6 (3.1)	23 (33)
Other, n (%)	2 (3.2)	6 (21)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	10 (7.8)	0 (0)	18 (9.2)	3 (4.3)
No treatment, n (%)	4 (6.3)	5 (18)	11 (52)	4 (12)	0 (0)	0 (0)	3 (8.3)	12 (9.4)	0 (0)	5 (2.6)	11 (16)

Note: COPD: chronic obstructive pulmonary disease; VTE: venous thromboembolism; LMWH: low molecular weight heparins; VKA: vitamin K antagonists

Table ii: Outcomes of the individual cohorts

Outcome after 6-month follow-up		First author of cohort										
		Sahut D'Izarn n=63	Shteinberg n=28	Tiseo n=21	Abdel-Razeq n=33	den Exter n=68	Soler n=204	Jimenez n=36	Donnelly n=128	Bozas n=81	Shinagare n=195	O'Connell n=69
Recurrent VTE	Only DVT, n (%)	0 (0)	-	4 (19)	0 (0)	3 (3.4)	3 (1.5)	0 (0)	3 (2.3)	2 (2.5)	4 (2.1)	-
	PE (±DVT), n (%)	5 (7.9)	-	1 (4.8)	0 (0)	2 (3.4)	3 (1.5)	2 (5.6)	3 (2.3)	1 (1.2)	5 (2.6)	-
	Any VTE, n (%)	5 (7.9)	3 (11)	5 (24)	0 (0)	5 (7.4)	6 (2.9)	2 (5.6)	6 (4.7)	3 (3.7)	9 (4.6)	-
Haemorrhage	Major, n (%)	3 (4.8)	3 (11)	0 (0)	1 (3.0)	7 (10)	5 (2.5)	2 (5.6)	4 (3.1)	1 (1.2)	12 (6.2)	-
	Fatal, n (%)	1 (1.6)	-	0 (0)	0 (0)	2 (2.9)	3 (1.5)	0 (0)	1 (0.8)	0 (0)	0 (0)	-
Mortality, n (%)		10 (16)	10 (36)	8 (38)	20 (61)	30 (44)	52 (25)	9 (25)	28 (35)	57 (45)	80 (41)	27 (39)

Note: VTE: venous thromboembolism; DVT: deep vein thrombosis; PE: pulmonary embolism

Table iii: Outcomes stratified for cancer type

Cancer type	Pooled 6-month risk of recurrent VTE % (95%CI)	Pooled 6-month risk of major haemorrhage % (95%CI)	Pooled 6-month mortality risk % (95%CI)
Lung	9.3 (4.2-16)	3.1 (1.1-6.1)	43 (31-55)
Colorectal	3.1 (1.0-6.4)	2.7 (0.46-6.8)	23 (17-29)
Other GI	6.0 (3.0-9.8)	7.0 (3.8-11)	47 (36-59)
Breast	11 (4.2-21)	7.2 (2.4-14)	25 (12-41)
Gynaecological	11 (4.6-19)	6.3 (1.9-13)	36 (21-52)
Other	3.2 (1.2-6.1)	8.0 (1.5-14)	35 (28-42)
Haematological	7.9 (2.1-17)	11 (3.9-21)	32 (19-46)

Note: GI: gastrointestinal; VTE: venous thromboembolism; CI: confidence interval

Table iv: Outcomes in patients with metastatic cancer and non-metastatic cancer

Stage of malignancy	Pooled 6-month risk of recurrent VTE % (95%CI)	Pooled 6-month risk of major haemorrhage % (95%CI)	Pooled 6-month mortality risk % (95%CI)
Metastatic	6.7 (3.2-11)	3.8 (1.6-6.8)	41 (34-48)
Non-metastatic	4.6 (1.8-8.6)	4.7 (2.2-8.1)	16 (8.1-25)

Note: VTE: venous thromboembolism; CI: confidence interval

Table v: Outcomes related to thrombus location

Thrombus location	Pooled 6-month risk of recurrent VTE % (95%CI)	Pooled 6-month risk of major haemorrhage % (95%CI)	Pooled 6-month mortality risk % (95%CI)
Central	5.6 (3.1-8.7)	4.4 (1.5-8.8)	42 (33-52)
Peripheral	6.6 (3.5-11)	4.7 (3.0-6.9)	30 (25-36)

Note: VTE: venous thromboembolism; CI: confidence interval